about
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activityDown titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activityDose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS studyNon-pharmacological care for patients with generalized osteoarthritis: design of a randomized clinical trialTight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.Time to achieve remission determines time to be in remission.Prevalence and predictors of health care use in patients with early hip or knee osteoarthritis: two-year follow-up data from the CHECK cohort.Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritisLow infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study.Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis.Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report.Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists.The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis.Development of quality indicators for monitoring of the disease course in rheumatoid arthritis.Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.The efficacy and safety of low-dose radiotherapy on pain and functioning in patients with osteoarthritis: a systematic review.Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study.Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study.What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?How should worsening in osteoarthritis be defined? Development and initial validation of preliminary criteria for clinical worsening in knee and hip osteoarthritis.Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms.The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial.Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review.Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009.Choosing wisely in daily practice: a mixed methods study on determinants of antinuclear antibody testing by rheumatologists.Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.The use of different methods for rapid determination of the ESR induces DAS28 misclassification in clinical practice.Disseminated Mycobacterium gordonae infection in a renal transplant recipient.Randomized trial of the effectiveness of a non-pharmacological multidisciplinary face-to-face treatment program on daily function compared to a telephone-based treatment program in patients with generalized osteoarthritis.[Serious infection due to biologicals: risk only mildly elevated in patients with rheumatoid arthritis].Personalizing treatment targets in rheumatoid arthritis by using a simple prediction model.Postural changes, dysphagia, and systemic sclerosis.The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients.
P50
Q24193435-550EEF73-BCF0-4EE9-AD0A-687B24BC4DBCQ24198056-078D9EBD-8C83-43BA-929F-9993529E2D62Q33590773-1769BBEC-B4FC-4580-81D4-7CC2D820B40EQ33622869-E1FE47D0-96D5-4CEF-8045-188CC9DCF72EQ33651502-98B173D6-62AF-4CD5-9703-15ABB5EC2B86Q33792680-F9567FFD-B405-48FF-A94A-4548C630EF4DQ34027517-E3347E10-F774-4DD5-B625-C8DD29F58E27Q34202198-6688B2DB-579F-4570-9294-177905BCAABBQ34211769-47C396E1-CFA4-427D-95E1-74691F474479Q34420269-BDB51029-D08F-4690-AE26-3649635D0BC0Q34730116-A0023D11-27C9-40AE-BBF1-CA13093798D1Q35065233-2A90FC97-C7BD-4717-8BA2-1ABD2F208BB5Q35188551-C55CF1C1-F64F-4EA6-AD33-38504921BB1CQ35550664-5B44BF75-062B-40FD-982E-5D31C6C7DB14Q35551481-AA664F50-266B-43A3-BAFA-1F84744CC317Q35579309-997E4DAB-ECB4-409F-AEBC-E71F686C76F8Q36151778-28444224-DC89-45A5-96A2-3315376FF770Q36399858-D98C7904-76BA-4D16-B604-CA77C2691872Q36933286-44DC41BC-B8B4-4F5B-9DB0-3E3650A10687Q37353452-C8099A2B-E372-4E4D-BD7B-785DE8B83E99Q37485377-8C0A2BB0-1B4E-40CA-A636-598EEFACC673Q38677219-6320E8C2-BFF5-4581-823E-EFFF50B76209Q38690799-203F9395-21C8-4BBE-A914-ED2E243C43EBQ38698322-92D04F5D-2963-48CB-9121-51A711730987Q38729061-6DACBB97-BA2A-4BB9-B7F7-F973DB14751FQ38839156-69C69565-366E-41A5-B385-D102AEBAF14CQ38918479-89161D40-65EB-4E56-8864-704D2E647C01Q39037812-D227CA7B-C346-40DD-B3E2-70B2779C704AQ39266482-C4174000-9057-4AB7-BE75-0C5903A927E1Q39420995-4EEBDC37-AB83-4255-8579-45C7D8079479Q39422221-4FF2ADE1-7FF7-4900-9B3A-BB0E59F4B81CQ39546255-280C0FD0-16B8-4A88-A8A3-5DC5EE850DEEQ40082040-4A9E796C-4928-402A-8DAB-8A81135F900AQ40354790-5AAFB473-1386-465F-9DF3-CA637E36729EQ40546053-FE661E99-66ED-43AE-9FF6-FA13329C5C05Q41051073-2C6A102F-219C-4DD5-80B0-8930E80A71D9Q41053975-1941DE46-4C15-4B96-ACBB-B058AF7B114AQ41576225-A34C119E-81D5-4D2B-A08F-3E07075F4E0CQ41827935-9153D2DB-3BFC-49B2-BED0-A33D592652C1Q43714093-35AD2047-3412-49E4-B51A-456F21379D4D
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Alfons A den Broeder
@ast
Alfons A den Broeder
@en
Alfons A den Broeder
@es
Alfons A den Broeder
@nl
Alfons A den Broeder
@sl
type
label
Alfons A den Broeder
@ast
Alfons A den Broeder
@en
Alfons A den Broeder
@es
Alfons A den Broeder
@nl
Alfons A den Broeder
@sl
altLabel
den Broeder AA
@en
prefLabel
Alfons A den Broeder
@ast
Alfons A den Broeder
@en
Alfons A den Broeder
@es
Alfons A den Broeder
@nl
Alfons A den Broeder
@sl
P1006
P214
P1006
P1053
H-4861-2016
P106
P21
P214
P31
P3829
P496
0000-0002-9012-4079
P734
P735
P7859
viaf-193121037